Navigation Links
PPD Names Mike Wilkinson Executive Vice President of Global Clinical Development
Date:3/31/2008

WILMINGTON, N.C., March 31 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced it has appointed Mike Wilkinson, Ph.D., as executive vice president of global clinical development. In this role, he will provide strategic leadership to the company's Phase II-IV operations in North America; Latin America; Europe, Middle East and Africa; and Asia Pacific.

"Mike Wilkinson brings an exceptional resume with strong leadership across a variety of roles and is uniquely qualified to direct our Phase II-IV global clinical development operations," said William Sharbaugh, chief operating officer. "With more than 25 years of project management experience, he is extremely skilled at building and leading successful project teams and will play a key role in helping us strategically expand our global operations."

Dr. Wilkinson most recently served as global head of internal medicine and vice president of project management for another contract research organization. His responsibilities included global operational and financial oversight and accountability for all internal medicine clinical trials. His industry experience also includes a tenure as clinical development project management practice leader at a pharmaceutical consulting organization.

Prior to joining the biopharmaceutical industry eight years ago, Dr. Wilkinson spent 27 years in the U.S. military where he began his career as a Navy SEAL. His many roles included aviation physiologist, White House liaison officer with Marine One Executive Transport, director of operations for the Joint Special Operations Medical Training Center and project director for the V-22 Osprey military aircraft.

He earned a doctorate in physiological optics from Indiana University, a master's degree from Penn State University and a bachelor's from Ohio University.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,200 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about the above-named employee's performance, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; competition within the outsourcing industry; rapid technological advances that make our products and services less competitive; continued success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; risks associated with and dependence on collaborative relationships; risks associated with the development and commercialization of drugs, including earnings dilution and obtaining regulatory approval; risks associated with acquisitions and investments, such as impairments; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts

Media:

Sue Ann Pentecost

+919 456 5890

sueann.pentecost@rtp.ppdi.com

Analysts/Investors:

Craig Eastwood

+910 558 7585

craig.eastwood@wilm.ppdi.com


'/>"/>
SOURCE PPD, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
2. Mediware Names Thomas K. Mann Chief Executive Officer
3. Cleveland-based Health Care Tech Company Within3 Names New CEO
4. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
5. Patient Safety Authority Board of Directors Names Infection Advisory Panel
6. Hooper Holmes Names Chris Behling President of Health & Wellness Division
7. MDMA Names New Director of Federal Affairs
8. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
9. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
10. MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors
11. Arthur M. Blank Family Foundation Names Susan Bertonaschi Program Officer, Better Beginnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... ... , ... "On Tour is a music themed slideshow production package which allows ... - CEO of Pixel Film Studios. , On Tour’s new slide presets come ... of their slideshows. Place each slide on top of another slide or piece of ...
(Date:1/15/2017)... ... January 15, 2017 , ... The ... is pleased to announce that it will be assisting HackensackUMC Mountainside with its ... Glen Ridge townships, servicing all surrounding towns. The firm will be working closely ...
(Date:1/14/2017)... California (PRWEB) , ... January 14, 2017 , ... "TransFreeze Volume 3 is a self ... freeze mask effect in Final Cut Pro X," said Christina Austin - CEO of Pixel ... create a unique freeze frame transition from one clip to the next. , ...
(Date:1/13/2017)... ... ... KOAMTAC ®, Inc., a leading manufacturer of Bluetooth barcode scanners and mobile ... collector at the National Retail Federation’s Big Show (NRF17) held January 15-17 in New ... need for more compact and rugged devices for collecting barcode data paired with a ...
(Date:1/13/2017)... Minneapolis, MN (PRWEB) , ... January 13, 2017 , ... ... have to endure jolts of pain whenever they brush their teeth. Sadly, most dental ... people who have sensitive gums and teeth. For these people, continuing their daily oral ...
Breaking Medicine News(10 mins):
(Date:1/15/2017)... -- ImmersiveTouch Inc., the global leader in virtual and ... strengthening their Executive Management team.  The Company ... Officer, Jay Banerjee as Chief Operating Officer, ... and Jia Luo , PhD as Vice President ... Bowman has 20 years experience commercializing innovative medical technologies. ...
(Date:1/13/2017)... Stock-Callers is currently reviewing the following ... WMGI ), Varian Medical Systems Inc. (NYSE: ... ), and NuVasive Inc. (NASDAQ: NUVA ). These ... a negative finish on Thursday, January 12 th , 2017, ... shares of health care companies in the S&P 500 were ...
(Date:1/13/2017)... 13, 2017 Wichita Laser Clinic ... treatments to Wichita, Kansas featuring ... treatments for skin rejuvenation, getting rid of unwanted tattoos, ... vascular lesions. "Since being in the aesthetics ... Wichita for laser tattoo removal and ...
Breaking Medicine Technology: